

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10534773
Filing Date	May 13, 2005
First Named Inventor	ROBERTSON, JOHN
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Sheet	1	of	10	Attorney Docket No: 49409-315804
-------	---	----	----	----------------------------------

U.S. PATENT DOCUMENTS

Examiner Initial *	Cite No	Document Number Number-Kind Code	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		2003/0008332A1	Jan 9, 2003	Ryan et al.	
		2003/0049692A1	Mar 13, 2003	Latov et al.	
		5501955	Mar 26, 1996	Bergman	
		5561049	Oct 1, 1996	Vold, B. et al.	
		5747268	May 5, 1998	Herring et al.	
		5763164	Jun 9, 1998	Calenoff	
		6387639	May 14, 2002	Posner, J. B., et al.	
		6645465	Nov 11, 2003	Hanash	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Patent Document Country Code Number Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	FIG
		WO-00/34787	Jun 15, 2000	ROBERTSON et al.		
		GB-2395270A	May 19, 2004	The University of Nottingham		
		WO-89/01153	Feb 9, 1989	Price et al.		
		WO-98/55872	Dec 10, 1998	AMDL, Inc.		
		WO-99/58978 A2	Nov 18, 1999	Nottingham, University of		
		GB-2007/003486	09-Dec-2007	ONCIMMUNE LTD		
		GB-2007/003486_SR	19-Dec-2007	ONCIMMUNE LTD		

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10534773
				Filing Date	May 13, 2005
				First Named Inventor	ROBERTSON, JOHN
				Art Unit	1643
				Examiner Name	Lynn Anne Bristol
Sheet	2	of	10	Attorney Docket No: 49409-315804	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AARONSON, S. A. et al., "Characterization of Murine Sarcoma Virus (KIRSTEN) Transformation of Mouse and Human Cells", <u>J. Gen. Virol.</u> 1971, 13: 245-252; 245-252	
		AGRAWAL, et al., "Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2", <u>Nature Medicine</u> January 1998, Vol. 4, No. 1, 43-49	
		AMBROSINI, G. et al., "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma", <u>Nature Med</u> 1997, 3(8), 917-21	
		ANGELOPOULOU, K. et al., "Detection of the TP53 Tumour Suppressor Gene Product and p53 Auto-antibodies in the Ascites of Women with Ovarian Cancer", <u>European Journal of Cancer</u> January 1997, Pergamon Press, Oxford, GB, Vol. 33, No. 1, 115-121	
		ANKER, et al., "K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer", <u>Gastroenterology</u> April 1997, Vol. 112, No. 4, 1114-1120	
		ASANO, et al., "Presence of anti-AFT-antibody producing B cells in peripheral blood lymphocyte of hepatocellular carcinoma patient", <u>Nippon Shokakibyo Gakkai Zasshi</u> February 1984, 81(2):278 (Abstract only)	
		AYALA, A. R. et al., "Human Chorionic Gonadotropin Immunoreactivity in Serum of Patients With Malignant Neoplasms", <u>Am J Reprod Immunol.</u> Apr-May 1983, 3(3), 149-51	
		BARAK, V. et al., "Clinical utility of cytokeratins as tumor markers", <u>Clin Biochem</u> July 2004, 37(7), 529-40	
		BASELGA, J. et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpressing Metastatic Breast Cancer", <u>J. Clin Oncol.</u> 1996, 14(3), 737-744	
		BEATTY, J. D. et al., "Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay", <u>Journal of Immunological Methods</u> 1987, 100, 173-179	
		BLOCK, T. M. et al., "Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans", <u>PNAS</u> Jan 18 2005, 102(3), 779-84	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10534773
Filing Date	May 13, 2005
First Named Inventor	ROBERTSON, JOHN
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Sheet

3

of

10

Attorney Docket No: 49409-315804

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOOYSE, F. M. et al., "Isolation and characterization of a urokinase-type plasminogen activator (MR = 54,000) from cultured human epithelial cells indistinguishable from urinary urokinase", <u>J Biol Chem</u> 1984, 259(11), 7198-205	
		BRAUN, S. et al., "Cytokeratin-Positive Cells in the Bone Marrow And Survival of Patients with Stage I, II, or III Breast Cancer", <u>N Engl J. Med</u> 2000, 342:8, 525-533	
		BUTLER, W. T. et al., "Osteopontin - Structure and biological activity", <u>CIBA Foundation Symposia</u> 1988, 136, 203-206	
		CALLANS, L. S. et al., "Raf-1 Protein Expression in Human Breast Cancer Cells", <u>Ann Surg Oncol</u> Jan 1995, 2(1):38-42	
		CARLSSON, HANS E. "Titration of antibodies to Salmonella O Antigens by Enzyme-Linked Immunosorbent Assay", <u>Infection and Immunity</u> Nov. 1972, Vol 6, No. 5, 703-708	
		CHARI, S. et al., "Partial-Purification of Inhibin from Human Testicular Extracts", <u>ACTA Endocrinologica</u> 1977, 85 Suppl 212, 215-219	
		CHEN, Y. T. "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening", <u>PNAS</u> 1997, 94, 1914-1918	
		CHINNI, R. S. et al., "Humoral Immune Responses to Cathepsin D and Glucose-regulated Protein 78 in Ovarian Cancer Patients", <u>Clinical Cancer Research</u> September, 1997, 3, 1557-1564	
		CLEMMENSEN, I. et al., "Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding-protein from human plasma -tetranectin", <u>Eur J. Biochem</u> 1986, 156(2), 327-333	
		COUSSENS, L. et al., "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene", <u>Science</u> 1985, 230, 1132-1139	
		DAHLBERG, T. "Enzyme-Linked Immunosorbent Assay for Titration of Haemophilus influenzae Capsular and O Antigen Antibodies", <u>Journal of Clinical Microbiology</u> Aug. 1980, Vol. 12, No. 2, 185-192	
		DEVINE, P. L. et al., "Circulating Mucins as Tumor Markers in Ovarian Cancer (Review)", <u>Anticancer Res.</u> May-Jun 1992, 12(3), 709-17	
		DIAMANDIS, E. P. et al., "Human Tissue Kallikreins: A Family of New Cancer Biomarkers", <u>Clin. Chem</u> Aug 2002, 48(8), 1198-1205	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: (initial) if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	10534773
Filing Date	May 13, 2005
First Named Inventor	ROBERTSON, JOHN
Art Unit	1643
Examiner Name	Lynn Anne Bristol

(Use as many sheets as necessary)

Sheet	4	of	10	Attorney Docket No: 49409-315804
-------	---	----	----	----------------------------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DIAMANDIS, et al., "The new human kallikrein gene family: implications in carcinogenesis", <u>Trends Endocrinol Metab</u> , 11(2) Mar 2000, 54-60	
		DOWNWARD, et al., "Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences", <u>Nature</u> 1984, 307, 521-527	
		ELLIS, I. O. et al., "A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization", <u>Histopathology</u> 1984, 8: 501-516	
		FERNANDEZ-MADRID, F. "Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer", <u>Cancer Research</u> 2004, 64, 5089-5096	
		FOSSA, A. et al., "Identification of a nucleolar protein No55 as a tumour-associated auto-antigen in patients with prostate cancer", <u>Br J Cancer</u> 2000, 83(6), 743-9	
		GASPERI-CAMPANI, et al., "Chromosomal alterations, biological features and in vitro chemosensitivity of SCLC-R1, a new cell line from human metastatic small cell lung carcinoma", <u>European Journal of Cancer</u> April 1998, Vol 34, No. 5, 724-730	
		GERKE, V. "Annexins: From Structure to Function", <u>Physiological Reviews</u> 2002, 82, 331-371	
		GIARDINA, P. C. "Effect of antigen coating conditions on enzyme-linked immunosorbent assay for detection of immunoglobulin G antibody to <i>Neisseria meningitidis</i> serogroup Y and W135 capsular polysaccharide antigens in serum", <u>Clin. Diagnostic Lab. Immunol.</u> 2003, Vol. 10, 1136-1140	
		GNUDI, L. et al., "Adenovirus-Mediated Gene Transfer of Dominant Negative Rasas17 in 3T3L1 Adipocytes Does Not Alter Insulin-Stimulated PI3-Kinase Activity or Glucose Transport", <u>Mol. Endocrinol.</u> 1997, 11(1), 67-76	
		GOYDOS, J. S. et al., "A Phase I Trial of a Synthetic Mucin Peptide Vaccine", <u>J. Surgical Res.</u> 1996, 63: 298-304	
		GRAHAM, R. A. et al., "The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine", <u>Cancer Immunol. Immunother.</u> 1996, 42:71-80	
		GREGORY, JR, J. J. et al., "alpha-Fetoprotein and beta-Human Chorionic Gonadotropin. Their Clinical Significance as Tumour Markers", <u>Drugs</u> Apr 1999, 57(4), 463-7	
		GRIFFITHS, B. et al., "Assignment of the polymorphic intestinal mucin gene MUC2 to chromosome-11p15", <u>Ann Hum Genet</u> 1990, 54:277-85	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) > Applicant to place a check mark here if English language translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known Application Number 10534773 Filing Date May 13, 2005 First Named Inventor ROBERTSON, JOHN Art Unit 1643 Examiner Name Lynn Anne Bristol	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	5	of	10	Attorney Docket No: 49409-315804	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T†
		HARLOW, E. et al., "Antibodies: A Laboratory Manual", <u>Cold Spring Harbor Laboratory</u> 1988, 211-227	
		HSU, W. M. et al., "GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastic tumors", <u>Int J Cancer</u> 03/01/2005, 113, 920-7	
		HUDELST, G. et al., "Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue", <u>Breast Cancer Res Treat.</u> Aug 2004, Vol. 86(3), 281-91	
		HUDSON, GAIL A. et al., "Method for Testing Antiserum Titer and Avidity in Nephelometric Systems", <u>Clinical Chemistry</u> 1981, Vol. 27, No. 11, 1838-1844	
		HUHTALA, M. L. et al., "Excretion of a tumor associated trypsin-inhibitor (TATI) in urine of patients with Gynecological Malignancy", <u>Int J Cancer</u> 1983, Vol. 31(6), 711-714	
		IBRAHIM, S. O. et al., "Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas", <u>Oral Oncology, Elsevier Science, Oxford, GB</u> May 1999, Vol.35, No. 3, 302-313	
		ISRAELI, R. S. "Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen", <u>Cancer Res.</u> 1993, 53:227-30	
		JAGER, D. "Cancer-Testis Antigens and ING1 Tumor Suppressor Gene Product Are Breast Cancer Antigens: Characterization of Tissue-specific ING1 Transcripts and a Homologue Gene", <u>Cancer Res</u> 12/15/1999, Vol. 59(24), 6197-6204	
		JAGER, D. et al., "Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library", <u>Cancer Res</u> 2001, Vol. 61(5), 2055-61	
		JAIS, et al., "Association of serum antibodies against p53 protein with poor survival in patients with Zollinger-Ellison Syndrome", <u>Gastroenterology</u> Jan. 1998, Vol. 114, No. 1, 37-43	
		JALANKO, et al., "Immunochemical properties of alpha-fetoprotein (AFP) and antibodies to autologous AFP", <u>Immunol. Commun</u> 1978, Vol. 7, No. 2, 209-222 (Abstract only)	
		JANEVAY, et al., "Competitive Inhibition Assay for Antigen in Unknown Samples", <u>Immunobiology</u> downloaded from url www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=imm.figgrp.2410, total 2 pages 2001	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw into through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant to place a check mark here if English language translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known Application Number 10534773 Filing Date May 13, 2005 First Named Inventor ROBERTSON, JOHN Art Unit 1643 Examiner Name Lynn Anne Bristol
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				
(Use as many sheets as necessary)				
Sheet	6	of	10	Attorney Docket No: 49409-315804

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JEROME, K. R. et al., "A Survivor of Breast Cancer with Immunity to MUC-1 Mucin, and Lactational Mastitis", <u>Cancer Immunology and Immunotherapy</u> January 1997, Berlin, DE, Vol. 43, No. 6, 355-360	
		KARLAN, B. Y. et al., "Peritoneal Serous Papillary Carcinoma, A Phenotypic Variant of Familial Ovarian Cancer: Implications for Ovarian Cancer Screening", <u>American Journal of Obstetrics & Gynecology</u> April 1999, Mosby, St. Louis, MO, Vol. 180, No. 4, 917-928	
		KASOF, G. M. et al., "Livin, a novel inhibitor of apoptosis protein family", <u>J Biol Chem</u> 2001, Vol. 276(5), 3238-46	
		KIEFER, M. C. et al., "The CDNA and derived amino-acid sequence for human Osteopontin", <u>Nucleic Acids Res</u> 1989, 17(8), 3306	
		KIM, H. et al., "Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer", <u>Br. J. Cancer</u> 2001, Vol. 84(5), 643-650	
		KIRCHOFF, C. "A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase-inhibitors", <u>Biology of Reproduction</u> 1991, 45(2), 350-357	
		KRAUSE, P. et al., "SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity", <u>J Immunol Methods</u> Dec 2003, Vol. 283, 261-7	
		KUMAR, S. et al., "Standardisation and comparison of serial dilutions and single dilution enzyme linked immunosorbent assay (ELISA) using different antigenic preparations of the Babesia (Theileria) equi parasite", <u>Veterinary Research</u> 2003, Vol. 34, No. 1, 71-83	
		LINDNER, P. et al., "Specific Detection of His-Tagged Proteins with Recombinant Anti-His Tag scFv-Phosphatase or scFv-Phage Fusions", <u>Bio Techniques</u> 1997, 22 (1), 140-149	
		LLOYD, K. O. et al., "Isolation and Characterization of Ovarian Cancer Antigen CA 125 Using a New Monoclonal Antibody (VK-8) Identification As a Mucin-Type Molecule", <u>Int. J. Cancer</u> 1997, 71: 842-850	
		MAEDA, A. et al., "Aberrant Expression of Photoreceptor-specific Calcium-binding Protein (Recoverin) in Cancer Cell Lines", <u>Cancer Res.</u> 2000 Apr. 1, 2000, 60(7):1914-20	
		MASHINO, K. et al., "Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas", <u>Br. J. Cancer</u> 2001, 85(5):713-720	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10534773
Filing Date	May 13, 2005
First Named Inventor	ROBERTSON, JOHN
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Sheet 7 of 10

Attorney Docket No: 49409-315804

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MCINTYRE, et al., "Oral contraceptive usage and the expression of CA 15-3 and C-erbB-2 in the saliva of healthy women", <u>Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.</u> Dec. 1999, Vol. 88, No. 6, 687-690	
		MEICHENIN, M. et al., "Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation", <u>Cancer Res.</u> 10/01/2000, 60 (19), 5499-507 (Abstract only)	
		MICROBIX BIOSYSTEMS INC., "Antigen titration using the Microbix IgG ELISA", <u>Product Technical Bulletin</u> , URL: http://web.archive.org/web/20050526231623/http://www.microbix.com/products/PDFs/TB-93-1AntigenTitrationusingtheMicrobixIgG+ELISA.pdf 2005	
		MOLL, R. et al., "The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells", <u>Cell</u> 11/31/1982, 31(1), 11-24	
		MUNEMITSU, S. et al., "Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein", <u>PNAS</u> 1995, 92: 3046-50	
		MUNOZ, et al., "New experimental criteria for optimization of solid-phase antigen concentration and stability in ELISA", <u>J. Immunol. Methods</u> 1986, 94:137-44 (Abstract only)	
		MURAKI, et al., "Assessment of serum CYFRA 21-1 in lung cancer", <u>Cancer</u> April 1996, 77(7), 1274-7	
		NAROD, "Genetic epidemiology of prostate cancer", <u>BBA-Reviews on Cancer</u> January 1999, Vol. 1423, No. 2, F1-F13	
		NORUM, L. F. et al., "Elevated CA 125 in Breast Cancer - A Sign of Advanced Disease", <u>Tumour Biol.</u> Jul-Aug 2001, 22(4), 223-8	
		PARE, J. et al., "An enzyme-linked immunosorbent assay (ELISA) for serological diagnosis of Neospora sp. infection in cattle", <u>Journal of Veterinary Diagnostic Investigation</u> 1995, Vol. 7, 352-359	
		PEDRERO, J. M. G. et al., "Annexin A1 Down-Regulation in Head and Neck Cancer Is Associated with Epithelial Differentiation Status", <u>American Journal of Pathology</u> 2004, 164(1), 73-79	
		PEREY, L. "Elevated CA125 levels in patients with metastatic breast carcinoma", <u>Br J Cancer</u> Oct. 1990, 62(4), 668-670	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10534773
Filing Date	May 13, 2005
First Named Inventor	ROBERTSON, JOHN
Art Unit	1643
Examiner Name	Lynn Anne Bristol

Sheet	8	of	10	Attorney Docket No: 49409-315804
-------	---	----	----	----------------------------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PRATT, M. A. et al., "Estrogen activates raf-1 kinase and induces expression of EGR-1 in MCF-7 breast cancer cells", <u>Mol Cell Biochem</u> Dec. 1998 , 189(1-2), 119-25	
		RAGHAV, G. P. et al., "Method for determining the affinity of monoclonal antibody using non-competitive ELISA: A computer program", <u>Journal of Immunoassay</u> 1994 , 15(2), 115-128	
		RAO, et al., "Detection of human ovarian tumor-associated antigens by antibodies isolated from ovarian carcinoma ascitic fluid", <u>Am J Obstet Gynecol</u> July 1998 , Vol. 159, 94-98	
		RASMUSSEN, et al., "An ELISA for the detection of anti-neutrophil cytoplasm antibodies (ANCA)", <u>J. Immunol. Methods</u> Feb 1990 , 127(1), 139-45 (Abstract only)	
		REDDISH, M. A. et al., "Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope siayl-Tn-KLH cancer vaccine in active specific immunotherapy", <u>Cancer Immunol. Immunother</u> 1996 , 42: 303-309	
		REITER, R. E. et al., "Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer", <u>PNAS</u> 1998 , 95:1735-1740	
		RIDDLE, O. et al., "The preparation, identification and assay of prolactin - A hormone of the anterior pituitary", <u>Am J. Physiol</u> 1933 , 105(1), 191-216	
		ROBERTSON, J.F. R. et al., "Assessment of Four Monoclonal Antibodies as Serum Markers in Breast Cancer", <u>Eur. J. Cancer</u> 1990 , 26: 1127-1132	
		ROBERTSON, J.F. R. et al., "Prospective assessment of the role of five tumour markers in breast cancer", <u>Cancer Immunol. Immunother</u> , 1991 , 33:403-410	
		ROBERTSON, et al., "Radioimmunohistochemistry of Epidermal Growth Factor Receptor in Breast Cancer", <u>Archives of Pathology and Laboratory Medicine</u> 2002, 128:177-81	
		RUGHETTI, et al., "Human B-Cell Immune Response to the Polymorphic Epithelial Mucin1", <u>Cancer Research</u> 06/01/1993 , 53, pp. 2457-2459	
		RUSCIANO, "Concomitant Purification of Prostatic Carcinoma Tumor Markers from Human Seminal Fluid Under Nondenaturing Conditions", <u>Clinical Chemistry</u> 1988 , Vol. 34, No. 12, 2528-2532	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	10534773
Filing Date	May 13, 2005
First Named Inventor	ROBERTSON, JOHN
Art Unit	1643
Examiner Name	Lynn Anne Bristol

(Use as many sheets as necessary)

Sheet	9	of	10	Attorney Docket No: 49409-315804
-------	---	----	----	----------------------------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SEABURY, C. A. et al., "Evaluation of a new serum testing method for detection of prostate cancer", <i>J Urol</i> Jul 2002 , 168(1):93-9 (Abstract only)	
		SOUSSI, T. "The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy", <i>Immunology Today</i> August 1996 , Elsevier Publications, Cambridge GB, Vol. 17, No. 8, 354-356	
		STANDKER, L. et al., "Isolation and characterization of the circulating form of human endostatin", <i>FEBS Lett</i> 1997 , 420 (2-3), 129-33	
		STIEBER, et al., "A new marker in lung cancer", <i>Cancer</i> Aug 1993 , 72(3), 707-13	
		STILLER, D. et al., "Immunohistochemical demonstration of alpha-fetoprotein in testicular germ cell tumors", <i>Acta Histochem Suppl.</i> 1986 , Supp - Band 33:225-31	
		STRNAD, N. et al., "Simple determination of polysaccharide specific antibodies by means of chemically modified ELISA plates", <i>Journal of Immunological Methods</i> 06/14/1996 , Elsevier Science Publishers B.V., Vol 193, No. 1, 1-7	
		SZALA, S. et al., "Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2", <i>PNAS</i> 1990 , 87:3542-3546	
		TAUCHI, K. et al., "Expression of heat shock protein-70 and c-myc protein in human breast-cancer - an immunohistochemical study", <i>Jap J Clin Oncol</i> 1991 , 21(4), 256-63	
		TAYLOR-PAPADIMITRIOU, "Report on the First International Workshop on Carcinoma-Associated Mucins", <i>Int. J. Cancer</i> 1991 , 49:1-5	
		THOMAS, W. M. et al., "Failure of CA19-9 to detect asymptomatic colorectal carcinoma", <i>Br. J. Cancer</i> 1991 , 63:975-976	
		TSAL, et al., "Relationship of serum alpha-fetoprotein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma", <i>Gastroenterol Jpn</i> June 1990 , 25(3), 338-93	
		TSUJIMOTO, Y. et al., "Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma", <i>PNAS USA</i> 1986 , 83(14), 5214-8	
		VAN MILLIGEN, FLORINE J. et al., "Calculation of the affinity constant KASS for solid phase antigen: A model system using monoclonal antibodies against the cat allergen Fel d I", <i>Journal of Immunological Methods</i> 1993 , 162:165-173	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known Application Number 10534773 Filing Date May 13, 2005 First Named Inventor ROBERTSON, JOHN Art Unit 1643 Examiner Name Lynn Anne Bristol	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					
Sheet	10	of	10	Attorney Docket No: 49409-315804	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VON MENSENDORF-POUILLY, S. "Humoral Immune Response to Polymorphic Epithelial Mucin (MUC-1) in patients with Benign and Malignant Breast Tumours", <u>European Journal of Cancer</u> 1996, Vol. 32A, No. 8, 1325-1331	
		WARRI, A. M. et al., "Anti-oestrogen Stimulation of ERBB2 Ectodomain Shedding from BT-474 Human Breast Cancer Cells with ERBB2 Gene Amplification", <u>Eur. J. Cancer</u> 1996, 32A: 134-140	
		WOLF, A. et al., "A Tumour-Associated Antigen from The Pleural Effusion of Patients with Squamous-Cell Carcinoma of Lung", <u>Br. J. Cancer</u> 1978, Vol. 36, 1046-1052	
		XING, P. X. et al., "Phase I study of synthetic MUC1 peptides in breast cancer", <u>Int. J. Oncol.</u> 1995, 6(6): 1283-1289	
		YAZICI, H. et al., "Amplification in tumors and benign tissue of breast cancer patients", <u>Cancer Lett.</u> 1996, 107: 235-239	
		YOUSEF, G. M. et al., "Expanded Human Tissue Kallikrein Family - A Novel Panel of Cancer Biomarkers", <u>Tumor Biol</u> 2002, 23, 185-192	
		ZEHEHNTNER, B. K. et al., "Mammaglobin as a Novel Breast Cancer Biomarker: Multigene Reverse Transcription-PCR Assay and Sandwich ELISA", <u>Clin Chem</u> Nov 2004, 50(11), 2069-76	
		ZEHEHNTNER, B. K. et al., "Mammaglobin: a candidate diagnostic marker for breast cancer", <u>Clin Biochem.</u> Apr 2004, 37(4), 249-57	
		ZIELEN, et al., "Simple determination of polysaccharide specific antibodies by means of chemically modified ELISA plates", <u>J. Immunol. Methods</u> June 1996, 193(1), 1-7	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached